10-K: MIRA Pharmaceuticals Reports 2025 Losses, Advances Pipeline

MIRA Pharmaceuticals reported significant net losses for 2025, raising going concern doubts, while advancing its drug candidates Ketamir-2, MIRA-55, and SKNY-1 through clinical and preclinical stages.

Summary

• MIRA Pharmaceuticals is a clinical-stage pharmaceutical development company focused on neurologic, neuropsychiatric, metabolic, and addiction-related disorders.
• The company completed a Phase 1 clinical trial for Ketamir-2 (oral NMDA receptor modulator) in healthy volunteers, reporting no serious adverse events or dose-limiting toxicities, with final analyses ongoing.
• A Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) is planned for the first half of 2026, subject to regulatory feedback and site readiness.
• MIRA-55, a novel oral, non-psychoactive cannabinoid analog, is in preclinical development for inflammatory pain and central nervous system conditions, showing analgesic and anti-inflammatory activity without typical cannabinoid CNS adverse effects.
• The company acquired SKNY Pharmaceuticals, Inc. on September 29, 2025, adding SKNY-1, a preclinical-stage oral therapeutic, to its pipeline.
• SKNY-1, designed to modulate CB1, CB2, and MAO-B pathways, demonstrated reductions in body weight, food consumption, and nicotine-seeking behavior in preclinical models without muscle loss or adverse CNS effects.
• The U.S. Drug Enforcement Administration (DEA) concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently considered controlled substances, which may facilitate their clinical development and commercialization.
• MIRA Pharmaceuticals reported a net loss of $10.4 million for the year ended December 31, 2025, an increase from $7.9 million in 2024.
• The company's accumulated deficit reached $39.6 million as of December 31, 2025.
• Cash and cash equivalents stood at $6.3 million as of December 31, 2025.
• The independent auditor's report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.
• Management expects current cash to fund operations into at least the first quarter of 2027 but acknowledges the need for additional capital.
• The company raised $6.7 million from At The Market (ATM) financings in 2025 and $3.6 million in 2024.
• CEO Erez Aminov received performance-based compensation totaling $5,304,174 in 2025, including a $80,753 cash bonus and 83,500 vested restricted stock units (valued at approximately $86,000) for achieving a Phase 1 clinical milestone.
• Kelly Stackpole informed the company on March 30, 2026, that he would not be joining the Board as a director candidate.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report, with substantial financial losses and an explicit going concern warning from auditors and management, despite positive early-stage clinical and preclinical data for its drug candidates. The need for significant future capital raises adds to the uncertainty.

Positives

• Ketamir-2 completed its Phase 1 clinical trial in healthy volunteers with no serious adverse events or dose-limiting toxicities reported, and no clinically significant dissociative or psychotomimetic effects, indicating a favorable safety profile.
• Ketamir-2 is advancing to a Phase 2a clinical trial in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026, targeting a condition with significant unmet medical need and no FDA-approved therapies.
• MIRA-55 demonstrated dual analgesic and anti-inflammatory effects in preclinical models without cannabinoid-like central nervous system side effects, suggesting a differentiated pharmacological profile.
• SKNY-1 showed significant weight loss without measurable muscle mass loss, reduced high-calorie food consumption, and reversal of nicotine-seeking behavior in preclinical models, along with a favorable central nervous system safety profile.
• The U.S. DEA concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently considered controlled substances, which may facilitate clinical development and commercialization by avoiding certain regulatory requirements.
• The strategic acquisition of SKNY Pharmaceuticals, Inc. expanded the company's pipeline with SKNY-1, targeting large and rapidly growing obesity and nicotine addiction markets.
• Management believes its differentiated pipeline is positioned to address gaps in large and growing therapeutic markets, including neuropathic pain, inflammatory pain, obesity, and nicotine dependence.
• The company successfully raised $6.7 million through At The Market (ATM) financing in 2025, providing capital for operations.
• Internal controls over financial reporting were deemed effective as of December 31, 2025, indicating improved financial oversight.

Negatives

• The company reported a net loss of $10.4 million for the year ended December 31, 2025, an increase from $7.9 million in 2024.
• The accumulated deficit grew to $39.6 million as of December 31, 2025, highlighting significant historical losses.
• The independent auditor's report contains an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• Management explicitly states that as of the filing date, the company has insufficient cash and cash equivalents to support its operations for at least the next 12 months.
• The company has no revenues and does not expect to generate revenue or achieve profit for many years, if at all.
• Significant and increasing liquidity needs will require additional funding, which may not be available on favorable terms or at all.
• Reliance on a limited number of suppliers for materials and components required to manufacture product candidates poses supply chain risks.
• Heavy reliance on third parties (Contract Research Organizations and Contract Development and Manufacturing Organizations) to conduct clinical trials and manufacturing introduces risks of delays, non-compliance, and increased costs.
• Conflicts of interest may arise due to the company's relationships with MIRALOGX LLC and Bay Shore Trust, which are related parties and significant shareholders.
• Key executive officers, including the CEO and CFO, are not employed on a full-time basis, which could adversely affect business operations.
• The company has no issued patent protection for MIRA-55, which could adversely impact its potential competitive position.
• SKNY Pharmaceuticals, Inc. (now a subsidiary) does not own the rights to SKNY-1, relying on a license from MIRALOGX LLC, which includes a minimum annual royalty payment of $250,000 once revenue is first received.
• The company has limited marketing experience and does not anticipate establishing its own sales force or distribution capabilities.
• The market value of voting and non-voting common equity held by non-affiliates was relatively small at $15,950,168 as of June 30, 2025.
• Sales of a significant number of shares by founding stockholders (Bay Shore Trust, MIRALOGX) could depress the market price of the common stock.
• CEO Erez Aminov did not report several grants and vesting of options and restricted stock units during the 2025 fiscal year, requiring a late Form 5 filing on February 17, 2026.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to no revenues, recurring operating losses, and negative cash flows from operations.
• The company's limited operating history makes it difficult for investors to accurately evaluate its operations and future prospects.
• Significant and increasing liquidity needs require additional funding, which may not be available on commercially reasonable terms or at all, potentially forcing delays or curtailment of development activities.
• The company has not generated revenues or achieved a profit and may not do so for many years, if ever, making its ability to continue as a going concern dependent on external capital.
• Conflicts of interest may arise between the company and MIRALOGX LLC, and the Bay Shore Trust, due to common ownership and licensing agreements, potentially affecting decision-making.
• Certain executive officers are not employed on a full-time basis, which could lead to conflicts of interest and impact the company's ability to address business challenges promptly.
• Future viability depends almost entirely on the successful preclinical and clinical development, regulatory approval, and commercialization of product candidates (Ketamir-2, MIRA-55, SKNY-1), which is a lengthy, expensive, and uncertain process.
• Results from preclinical studies and earlier clinical trials are not necessarily predictive of future results, and drug candidates frequently fail in later clinical stages.
• Product candidates, if approved, may not achieve expected market acceptance due to factors like efficacy, safety, pricing, reimbursement, and competition.
• The company has limited marketing experience and does not anticipate establishing its own sales force, relying on third parties for commercialization, which may not be successful.
• If prices for future approved products decrease or if government and other third-party payers do not provide adequate coverage and reimbursement, revenue and profitability will suffer.
• The company expects to face intense competition from larger, more experienced pharmaceutical and biotechnology companies with greater resources.
• Product shipment delays could occur due to import/export license requirements and transit issues, potentially leading to product damage and revenue loss.
• The DEA's classification of Ketamir-2, MIRA-55, and SKNY-1 as non-controlled substances is not assured to remain unchanged, which could complicate development.
• The manufacture of product candidates is complex and uncertain, with risks of difficulties in scaling up, meeting quality standards, and obtaining GMP compliance, potentially delaying clinical trials.
• Business interruptions (e.g., fire, theft, loss of raw materials) at contracted manufacturing or laboratory facilities could delay product development and disrupt sales.
• Product liability lawsuits related to testing or commercialization of product candidates could result in substantial liabilities, reputational harm, and limitations on commercialization.
• Counterfeit versions of products could harm the business by affecting patient confidence and causing reputational and financial damage.
• Dependence on key personnel and the ability to attract and retain qualified scientific, technical, and managerial staff is critical in a highly competitive field.
• Employee misconduct, including non-compliance with regulatory standards or improper use of information, could lead to government investigations, penalties, and reputational harm.
• Non-compliance with U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control and customs laws, could result in civil or criminal penalties.
• Loss of proprietary information or security breaches of IT systems could compromise sensitive data, disrupt operations, and expose the company to legal claims and penalties.
• Legislative or regulatory reform of the U.S. healthcare system, including changes to the Affordable Care Act, could adversely affect the ability to profitably sell products.
• Unfavorable global economic and geopolitical conditions (e.g., wars, inflation) could adversely affect business, financial condition, and stock price.
• Future acquisitions could divert management's attention, result in shareholder dilution, and disrupt operations.
• Clinical trials are expensive, time-consuming, uncertain, and susceptible to change, delay, or termination by regulatory agencies or the company itself.
• Clinical trials of synthetic cannabinoid drug candidates and ketamine analogs are novel with limited historical data, posing a significant risk that trials will not result in commercially viable drugs.
• The regulatory approval processes with the FDA are lengthy and inherently unpredictable, with no guarantee of approval even if clinical endpoints are met.
• Violation of federal or state fraud and abuse laws could lead to penalties, exclusion from healthcare programs, and adverse effects on business.
• Serious adverse events or other safety risks could require abandonment of development, delay or limit approval, restrict labeling, or cause product recalls.
• Reliance on third-party Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for clinical trials and manufacturing exposes the company to risks of non-performance, delays, and quality issues.
• Inability to adequately protect intellectual property (patents, trade secrets) could lead to competition from generic or similar products; specifically, there is no patent protection for MIRA-55.
• SKNY Pharmaceuticals, Inc. does not own the rights to SKNY-1, relying on a license from MIRALOGX LLC, which includes minimum annual royalty obligations and risks of license termination upon breach.
• Failure to maintain compliance with Nasdaq Listing Rules could result in delisting, limiting the trading market for shares and making future financing more difficult.
• Delisting from Nasdaq could subject shares to the SEC's penny stock rules, making it more difficult for shareholders to purchase or sell.
• Certain provisions of Florida law and the company's articles of incorporation and bylaws may have anti-takeover effects, discouraging acquisitions even if beneficial to shareholders.
• Future offerings of equity securities will likely dilute the proportionate interest of existing shareholders.
• The potential issuance of preferred stock in the future could make it difficult for another company to acquire the company or adversely affect common stockholders.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.

Future Outlook

The company plans to initiate a Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026, pending regulatory feedback and site readiness. It is targeting Investigational New Drug (IND) submissions for MIRA-55 and SKNY-1 in 2026, contingent on completing required preclinical studies, manufacturing readiness, regulatory interactions, and available capital. Management expects existing cash and cash equivalents to fund operations into at least the first quarter of 2027 but anticipates needing additional capital through various financing and strategic transactions. The company also intends to evaluate additional indications for Ketamir-2 and explore strategic partnerships for later-stage development and commercialization across its pipeline, with an objective to monetize product candidates at the end of planned Phase II studies.

Management Comments

• MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders.
• Based on preliminary safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported for Ketamir-2 in its Phase 1 trial; however, the database remains blinded and final audited safety and pharmacokinetic analyses are ongoing.
• The U.S. Drug Enforcement Administration (DEA) has completed its scientific review of Ketamir-2, MIRA-55, and SKNY-1 and concluded that each compound is not currently considered a controlled substance or listed chemical under the Controlled Substances Act (CSA) and applicable regulations.
• The company believes Ketamir-2 may offer advantages including oral administration, reduced abuse potential, and improved tolerability, positioning it as a potential alternative to existing therapies.
• The company believes MIRA-55's differentiated pharmacological profile may position it as a potential non-opioid alternative in the treatment of inflammatory pain.
• The company believes SKNY-1's oral administration, multi-target mechanism, and dual indication potential may position it as a differentiated candidate across both obesity and addiction markets.
• Our objective is to generate clinical data demonstrating safety, tolerability, and preliminary efficacy in patients for Ketamir-2's Phase 2a study.
• Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.

Industry Context

StockSavvy.ai notes that MIRA Pharmaceuticals operates in highly competitive therapeutic areas, including neuropathic pain, inflammatory pain, obesity, and nicotine dependence, which are characterized by limitations in existing therapies. The company's strategy to develop differentiated small-molecule therapeutics, such as Ketamir-2 (oral NMDA receptor modulator), MIRA-55 (non-psychoactive cannabinoid analog), and SKNY-1 (multi-pathway modulator), aims to address significant unmet medical needs in these large and growing markets. The DEA's non-controlled substance classification for its pipeline candidates could provide a competitive advantage by simplifying regulatory pathways compared to other cannabinoid or ketamine-based treatments. However, the industry is dominated by multinational pharmaceutical and biotechnology companies with substantially greater financial, technical, and commercial resources, posing a significant challenge for MIRA's commercialization efforts.

Comparison to Industry Standards

• Ketamir-2 is designed to selectively modulate the NMDA receptor with low binding affinity and limited off-target activity, aiming for improved tolerability relative to ketamine, which has broader receptor binding and associated dissociative/psychotomimetic effects. This positions Ketamir-2 as a potential alternative to existing off-label treatments for chemotherapy-induced peripheral neuropathy (CIPN), such as antidepressants, anticonvulsants, and opioids, which often provide incomplete relief and have significant side effects.
• MIRA-55 demonstrated analgesic effects comparable to morphine in preclinical studies but with direct anti-inflammatory activity not observed with opioid treatment, and without typical cannabinoid-like central nervous system adverse effects. This differentiates it from traditional opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), both of which are associated with significant safety limitations, including dependence risk and gastrointestinal/cardiovascular adverse effects.
• SKNY-1 showed significant weight loss without measurable muscle mass loss in preclinical models, a potential advantage over current obesity therapies like GLP-1 receptor agonists, which can be associated with loss of lean muscle mass. It also targets nicotine dependence, an area where existing therapies are associated with modest long-term success rates and, in some cases, neuropsychiatric safety concerns.
• The company's pipeline aims to address limitations in existing therapies, including safety, tolerability, and long-term efficacy, aligning with a broader industry trend towards developing more targeted and safer drug profiles to meet unmet medical needs.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending against the company that are expected to have a material adverse effect on its business and financial condition.
• The company anticipates expending significant financial and managerial resources in the future to defend its intellectual property rights and against claims of infringement by third parties.
• On April 24, 2024, the company settled a claim under Section 16 of the Securities Exchange Act, requiring Bay Shore Trust to disgorge $148,703 in illegal profits back to the company.

Related Party Transactions

• **MIRALOGX LLC**: The company licenses U.S., Canadian, and Mexican patent rights for Ketamir-2 and SKNY-1 from MIRALOGX. MIRALOGX is a related party due to common founder (Jonnie Williams, Jr.) and ownership by Bay Shore Trust (the company's largest shareholder).
• **Ketamir-2 License Agreement (Nov 15, 2023)**: The company paid MIRALOGX a one-time, nonrefundable payment of $0.1 million and is obligated to pay an 8% royalty on net sales and other revenue from licensed products. A common stock purchase warrant to buy 700,000 shares at $2.00/share was also issued to MIRALOGX.
• **SKNY-1 License Agreement (Mar 16, 2025)**: Acquired through the SKNY acquisition, this license obligates the company to pay an 8% royalty on net sales of SKNY-1, with a minimum annual royalty of $250,000 beginning in the first year revenue is received.
• **Promissory Note and Loan Agreement (Nov 15, 2023)**: The company could borrow up to $3.0 million from MIRALOGX to fund Ketamir-2 development. This agreement expired on November 15, 2024, and no funds were borrowed in 2024 or 2025.
• **Bay Shore Trust**: The company's largest stockholder and owner of MIRALOGX. A Promissory Note and Loan Agreement (April 28, 2023) for up to $5.0 million was paid off by December 31, 2023. A common stock purchase warrant to buy 1,000,000 shares at $5.00/share was issued to Bay Shore Trust.
• **Section 16 Claim Settlement (April 24, 2024)**: Bay Shore Trust disgorged $148,703 in illegal profits from stock transactions involving insiders back to the company.
• **SKNY Pharmaceuticals, Inc. Acquisition (Sep 29, 2025)**: Acquired through a stock-for-stock merger. SKNY was a related party due to common shareholders and a shared licensor (MIRALOGX). As part of the acquisition, the company received 3,521,127 shares of Telomir Pharmaceuticals, Inc. common stock.
• **Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)**: A publicly traded preclinical stage biotechnology company, considered a related party due to common ownership, officers, and directors (e.g., Erez Aminov, Alan Weichselbaum, Matthew Whalen, Matthew Del Giudice, Edward MacPherson serve as directors/officers for both).
• **Erez Aminov (CEO)**: Owed an aggregate of $572,865 as of December 31, 2025, primarily related to accrued compensation and advances. Mr. Aminov is the son-in-law of Jonnie Williams, the owner of MIRALOGX.

Stakeholder Impact

• **Shareholders**: Face significant risk due to the company's going concern doubt, recurring losses, and reliance on future capital raises, which could lead to substantial dilution. The stock is highly speculative, but successful pipeline development could offer long-term value. Sales by large founding shareholders could depress the stock price.
• **Employees**: Continued employment and the value of stock-based compensation are contingent on the company's ability to secure funding and successfully advance its drug candidates.
• **Customers (future)**: Potential for novel therapeutics (Ketamir-2, MIRA-55, SKNY-1) to address significant unmet medical needs in areas like neuropathic pain, inflammatory pain, obesity, and nicotine dependence, offering new treatment options.
• **Suppliers and Creditors**: May face risks related to the company's financial stability and ability to meet contractual obligations, particularly given the going concern warning.
• **Regulatory Authorities**: The company's ongoing clinical trials and IND submissions require continued engagement and compliance with FDA and DEA regulations, with favorable DEA classifications potentially streamlining development.

Next Steps

• Initiate Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026, subject to regulatory feedback and site readiness.
• Submit Phase 2a protocol and supporting documentation for Ketamir-2 to the U.S. Food and Drug Administration (FDA) in the first half of 2026.
• Advance MIRA-55 through IND-enabling development activities.
• Target an Investigational New Drug (IND) submission for MIRA-55 for inflammatory pain.
• Conduct additional preclinical studies for SKNY-1.
• Advance SKNY-1 toward IND-enabling development activities.
• Target an Investigational New Drug (IND) submission for SKNY-1 in 2026.
• Secure additional capital, potentially through public or private equity offerings, strategic transactions, licensing, grants, or debt.
• Evaluate additional indications for Ketamir-2 where NMDA receptor modulation may have therapeutic relevance, including neuropsychiatric disorders.
• Explore strategic partnerships to support later-stage development and potential commercialization across the pipeline.
• Monetize product candidates (Ketamir-2, MIRA-55, SKNY-1) at the end of planned Phase II studies.

Key Dates

Recommendation

A seasoned investor would view the explicit 'going concern' warning from both the auditors and management, coupled with increasing net losses and a substantial accumulated deficit, as a critical red flag. While the pipeline shows promise in early stages and the DEA classification is favorable, the fundamental financial instability and heavy reliance on future, uncommitted capital raises present an unacceptably high level of risk. The potential for significant dilution from future equity offerings and the lack of near-term revenue generation further diminish the investment appeal. The stock is highly speculative, and the downside risk outweighs the speculative upside potential at this stage.

Keywords

Pharmaceuticals, Clinical-stage, Neurologic disorders, Neuropsychiatric disorders, Metabolic disorders, Addiction-related disorders, Ketamir-2, NMDA receptor modulator, Chemotherapy-induced peripheral neuropathy, Phase 1 clinical trial, Phase 2a clinical trial, MIRA-55, Cannabinoid analog, Inflammatory pain, Central nervous system, Preclinical development, IND submission, SKNY-1, CB1 receptor, CB2 receptor, MAO-B inhibitor, Obesity, Nicotine dependence, DEA classification, SEC filing, 10-K, Going concern, Financial losses, Capital raise, Stock options, Restricted stock units, Corporate governance, Intellectual property, Related party transactions, Biotechnology